First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.

@article{Lalani2017FirstlineSO,
  title={First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.},
  author={Aly-Khan A Lalani and Haocheng Li and Daniel Yick Chin Heng and Lori A. Wood and Austin Kalirai and G A Georg Bjarnason and Hao-Wen Sim and Christian K. Kollmannsberger and Anil B. Kapoor and S{\'e}bastien J. Hotte and Marie Vanhuyse and Piotr Marek Czaykowski and Michael Reaume and Denis Souli{\'e}res and Peter M. Venner and Scott A. North and Naveen S Basappa},
  journal={Canadian Urological Association journal = Journal de l'Association des urologues du Canada},
  year={2017},
  volume={11 3-4},
  pages={112-117}
}
INTRODUCTION Clinical trial data has shown pazopanib to be non-inferior in overall survival (OS) compared to sunitinib as first-line treatment for metastatic renal cell carcinoma (mRCC). The purpose of this study was to evaluate outcomes and compare dose-modifying toxicities of mRCC patients treated with suntinib or pazopanib in the real-world setting. METHODS Data were collected on mRCC patients using the prospective Canadian Kidney Cancer Information System (CKCis) database from January… CONTINUE READING